Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
actome logo — Next Generation Discovery

actome

Next Generation Discovery

Founded 2016 Germany Germany 15 employees Seed Total: $2.50M Biopharma, Biotechnology +1

General Information

Company Name actome
Founded Year 2016
Location Germany Germany
Employees 15
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with actome. To contact actome, visit actome.de.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does actome compare?

A PDF of actome and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting actome soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About actome

Actome is a Germany-based startup at the forefront of revolutionizing life science research and medical innovations with its proprietary Protein Interaction Coupling (PICO) technology. This groundbreaking technology allows for the quantification of proteins, protein interactions, and post-translational modifications in biological samples with unprecedented sensitivity and specificity, addressing the need for highly sensitive analysis of biomarkers in personalized healthcare and drug target interactions in research.

Actome not only provides assay kits but also offers a bioinformatics software as a service for result analysis, aiming to make the process more accessible and user-friendly. Moreover, the flexibility of their technology allows for the measurement of a large number of interactions simultaneously, using only minute amounts of biological samples, such as single cells.

Recognized for its innovative approach, Actome has received notable acclaim, including winning several business plan competition awards in 2019 and being listed among the top 50 startups in Germany in 2020. The company's momentum was further fueled by a recent Seed Round investment in December 19, 2022 led by The European Innovation Council. This injection of funds positions Actome for continued growth and impact in the Biopharma and Biotechnology industries.

Business keywords: Proteomics, Life Science Research, Medical Innovations, Biomarker Analysis, Protein Interaction Analysis, Post-translational Modification, Personalized Healthcare, Cellular Interaction Pathways, Drug Target Interactions, Assay Kits, Bioinformatics Software, Digital PCR, Biochemical Analysis, Innovative Technology, Start-up

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
European Innovation Council
European Innovation Council
19 Dec 2022
Grant €2.50M 1
European Innovation Council
European Innovation Council
05 Oct 2022
Seed Round Undisclosed 2
b.value AG
b.value AG, Qiagen
01 Jul 2021

actome Alternatives & Competitors

View All Alternatives
actome vs
Travera
Travera United States

Revolutionizing Cancer Therapy Guidance.

Non Equity Assistance
11 employees
Biotechnology, Health Care
actome vs
Glyphic Biotechnologies
Glyphic Biotechnologies United States

Next Generation Protein Sequencing.

Seed
34 employees
Biotechnology, Health Care
actome vs
trenzyme GmbH
trenzyme GmbH Germany

As full service provider for the life science industry, we have a clear mission: Accelerating your i...

22 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About actome

Next Generation Discovery
actome was founded in 2016.
actome is headquartered in Germany.
actome operates in Biopharma, Biotechnology and Life Sciences. Its work centres on Proteomics, Life Science Research, Medical Innovations and Biomarker Analysis.
actome has approximately 15 employees.
actome has completed 3 funding rounds, raising a total of $2.50M. The latest funding stage is Seed.
Top alternatives and competitors to actome include Travera, Glyphic Biotechnologies, trenzyme GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
actome and Travera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for actome, https://bouncewatch.com/company/actome, updated 19 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes